Treximo

09/28/2021

The treatment of glioblastomas remains extremely challenging. However, Glioblastoma brain tumors have been shown to have receptors to cannabinoids on their cell surfaces, that's why the University of Leeds (UK) will run a Phase-II trial using a cannabis-based drug, Sativex, for treating these aggressive brain tumors: https://bit.ly/2WEE3gM

The University of Leeds is set to lead a Phase II trial to evaluate the use of a cannabis-based drug, Sativex, for aggressive brain tumours.

09/27/2021

AstraZeneca's drug Saphnelo for the treatment of Systemic Lupus wins FDA approval. This is the first drug approved since 2011 for this disease: https://bit.ly/3ysjNML

The regulator cleared Saphnelo despite mixed clinical trial data, giving patients another option after the recent OK for a drug aimed at the autoimmune disease's severe side effects.

09/23/2021

Currently, there are no FDA or European Medicines Agency approved treatments for Alopecia Areata, a rare autoimmune disease in which the immune system attacks the hair follicles, leading to hair loss. However, Pfizer reported positive top-line data on its clinical trial for Ritlecitinib with a 20% or less scalp hair loss: https://bit.ly/3jqrUoK

Pfizer has reported positive top-line data from the Phase IIb/III ALLEGRO trial of its drug, ritlecitinib, in alopecia areata patients.

09/21/2021

Is it software testing your quality assurance method? You can go one step further and avoid issues from the start with a Software Quality Assurance (SQA). High-quality developers who use SQA spend 22% less time fixing issues typically found during testing.

Whether you’re developing an EDC system for clinical patient data or your business uses data science to extrapolate interesting clinical trial information, SQA will help you solve problems before you have them. With Treximo’s technology consulting services, we can ensure your software is quality-checked and constantly improved. Learn more about SQA here: https://treximo.com/blog/what-is-software-quality-assurance/

09/20/2021

Johnson & Johnson is inspiring patients through Twitter. In this program, patients recount their health stories and explain how a drug from J&J Janssen unit changed their lives. This is intended to bring people together, inspire and bring hope https://bit.ly/3gL1wV7

If you want to connect with and inspire your audience, tell them a story. That may be a marketing mantra, but it’s also the premise behind Johnson & Johnson's SHARE Network, a program that asks patients to recount their health stories—and share how a treatment from its Janssen unit changed their...

09/16/2021

"Roche said its cancer drug Polivy combined with a common chemotherapy regimen held lymphoma in check for longer than the standard drugs alone in patients who had not been previously treated. The drug is the first treatment shown to improve outcomes in these patients in 20 years".

Read the full story here: https://www.biopharmadive.com/news/roche-polivy-first-line-lymphoma-car-t-study/604660/

Positive data for the Swiss pharma's antibody-based drug could be a benchmark for CAR-T therapies, which other developers aim to move into early lymphoma treatment, too.

09/14/2021

A change in management is always a big challenge, especially in life-science companies. Treximo has experience with Top pharmaceutical companies to lead these processes and achieve the desired results that can also be applied to your company when needed.

Get to know how we help life-science companies with Clinical Monitoring Change Management here: https://treximo.com/blog/case-study/clinical-monitoring-change-management/

09/13/2021

A bioerodible implant with sustained-release technology will help prevent HIV infection and also provide birth control.

Inflammasome Therapeutics, which is behind this development, just received a grant from The Bill & Melinda Gates Foundation worth $1.3 million to continue this project, aligned with its objective of HIV prevention and expanding the range of contraceptive options for women: https://bit.ly/3kAUJ15.

Inflammasome Therapeutics has received funding to develop a sustained-release formulation that provides protection from HIV infection and birth control for 12 months. The Bill & Melinda Gates Foundation is bankrolling the project through a $1.3 million grant.

09/09/2021

Did you know that for every $1B invested in the US, $122M is lost to poor project management? Most businesses waste 12% on inefficiencies that project management can solve.

Discover the 6 benefits you can have in your Life-Science Company with a customized PMO service to manage many ongoing projects across various job sites, creating efficiency in resources and money: https://treximo.com/blog/6-benefits-of-custom-pmo-design/

09/07/2021

News on breast cancer treatment development: AstraZeneca and Daiichi Sankyo have reported positive results from the Phase III DESTINY-Breast03 clinical trial of Enhertu, which can boost survival among patients with breast cancer. The trial also showed potential to enhance overall survival. https://bit.ly/38n7dnh

AstraZeneca and Daiichi Sankyo have reported positive results from the Phase III trial of Enhertu in HER2-positive breast cancer patients.

09/02/2021

A significant breakthrough might be coming by the end of the year, led by GentiBio, which recently gained funding of $157 million. GentiBio is developing regulatory T-Cell Therapies to cure and treat Type 1 diabetes and some auto-immune and inflammatory diseases. Read the whole story here: https://bit.ly/2WFBzz6

The biotech company is working with regulatory T cells, an immune cell type that's become the focus of several newly launched drugmakers like Abata Therapeutics and Sonoma Biotherapeutics.

08/26/2021

Medical Writing is critical when working on a New Drug Application.

At Treximo, we bring the most experienced resources with deep subject matter expertise to the table, ensuring the best fit with your overall project team. The result is a high-quality deliverable tailored to the appropriate reviewer audience.

Read the whole Case Study here: https://bit.ly/3lp9juK